Zacks Investment Research downgraded shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) from a hold rating to a sell rating in a research note published on Saturday morning.

According to Zacks, “Spark Therapeutics, Inc. offers gene therapy. The Company’s product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. “

ONCE has been the subject of a number of other reports. BMO Capital Markets reaffirmed an outperform rating and set a $69.00 price objective on shares of Spark Therapeutics in a research note on Friday, April 7th. Stifel Nicolaus reaffirmed a buy rating and set a $76.00 price objective on shares of Spark Therapeutics in a research note on Monday, April 10th. Jefferies Group LLC reaffirmed a hold rating and set a $59.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, April 26th. Cantor Fitzgerald set a $94.00 price objective on shares of Spark Therapeutics and gave the company a buy rating in a research note on Tuesday, May 9th. Finally, Wedbush reaffirmed an underperform rating and set a $28.00 price objective on shares of Spark Therapeutics in a research note on Wednesday, May 10th. Two analysts have rated the stock with a sell rating, two have given a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $82.27.

Spark Therapeutics (NASDAQ:ONCE) opened at 78.63 on Friday. The stock has a 50 day moving average of $63.15 and a 200-day moving average of $58.70. Spark Therapeutics has a 52-week low of $35.07 and a 52-week high of $79.64. The firm’s market cap is $2.44 billion.

Spark Therapeutics (NASDAQ:ONCE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.75) by $0.14. Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The business had revenue of $1.48 million for the quarter, compared to the consensus estimate of $1.33 million. During the same quarter last year, the business posted ($1.04) EPS. The business’s revenue for the quarter was up 14.7% on a year-over-year basis. On average, analysts expect that Spark Therapeutics will post ($7.35) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another publication, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/08/08/spark-therapeutics-inc-once-downgraded-by-zacks-investment-research.html.

In other news, CFO Stephen W. Webster sold 2,337 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $71.12, for a total value of $166,207.44. Following the completion of the sale, the chief financial officer now directly owns 4,837 shares of the company’s stock, valued at $344,007.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Stephen W. Webster sold 7,663 shares of the stock in a transaction that occurred on Monday, June 19th. The stock was sold at an average price of $60.00, for a total transaction of $459,780.00. Following the completion of the sale, the chief financial officer now directly owns 10,163 shares of the company’s stock, valued at $609,780. The disclosure for this sale can be found here. Insiders sold 314,310 shares of company stock valued at $21,866,838 over the last three months. 7.30% of the stock is owned by insiders.

Several hedge funds have recently bought and sold shares of ONCE. BNP Paribas Arbitrage SA raised its stake in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock worth $174,000 after buying an additional 2,449 shares during the period. Highbridge Capital Management LLC bought a new stake in Spark Therapeutics during the first quarter worth about $227,000. KCG Holdings Inc. raised its stake in Spark Therapeutics by 9.4% in the first quarter. KCG Holdings Inc. now owns 6,247 shares of the biotechnology company’s stock worth $333,000 after buying an additional 538 shares during the period. State Board of Administration of Florida Retirement System raised its stake in Spark Therapeutics by 4.1% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 8,204 shares of the biotechnology company’s stock worth $409,000 after buying an additional 320 shares during the period. Finally, Legal & General Group Plc raised its stake in Spark Therapeutics by 16.8% in the second quarter. Legal & General Group Plc now owns 8,931 shares of the biotechnology company’s stock worth $532,000 after buying an additional 1,286 shares during the period. 88.95% of the stock is owned by institutional investors and hedge funds.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.